Zacks: Brokerages Expect TG Therapeutics, Inc (TGTX) Will Post Earnings of -$0.55 Per Share

Equities analysts expect TG Therapeutics, Inc (NASDAQ:TGTX) to report earnings of ($0.55) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for TG Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.58). TG Therapeutics reported earnings of ($0.45) per share in the same quarter last year, which would indicate a negative year over year growth rate of 22.2%. The company is expected to report its next earnings results on Wednesday, August 8th.

According to Zacks, analysts expect that TG Therapeutics will report full-year earnings of ($1.99) per share for the current financial year, with EPS estimates ranging from ($2.36) to ($1.34). For the next year, analysts forecast that the company will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.50) to ($1.66). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.15). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 87,025.00% and a negative return on equity of 170.83%.

A number of research firms have issued reports on TGTX. ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 5th. Zacks Investment Research raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 16th. B. Riley reaffirmed a “buy” rating and issued a $27.00 price objective (up previously from $21.50) on shares of TG Therapeutics in a research note on Friday, March 9th. Finally, Raymond James reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Wednesday, April 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. TG Therapeutics has an average rating of “Buy” and an average target price of $24.60.

NASDAQ:TGTX opened at $14.05 on Friday. TG Therapeutics has a 1 year low of $13.48 and a 1 year high of $13.80. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -7.36 and a beta of 1.21.

Large investors have recently added to or reduced their stakes in the business. Senzar Asset Management LLC increased its stake in TG Therapeutics by 56.9% in the 4th quarter. Senzar Asset Management LLC now owns 1,355,178 shares of the biopharmaceutical company’s stock worth $11,112,000 after acquiring an additional 491,678 shares during the last quarter. CIBC World Markets Inc. bought a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $250,000. University of Notre Dame DU Lac bought a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $2,483,000. Allianz Asset Management GmbH increased its position in shares of TG Therapeutics by 6.6% during the 4th quarter. Allianz Asset Management GmbH now owns 137,980 shares of the biopharmaceutical company’s stock valued at $1,131,000 after purchasing an additional 8,602 shares during the last quarter. Finally, Dupont Capital Management Corp increased its position in shares of TG Therapeutics by 153.1% during the 4th quarter. Dupont Capital Management Corp now owns 64,957 shares of the biopharmaceutical company’s stock valued at $533,000 after purchasing an additional 39,295 shares during the last quarter. 47.35% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit